Am J Perinatol 2013; 30(05): 347-352
DOI: 10.1055/s-0032-1326985
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Role of Novel Biomarkers in Early Diagnosis and Prognosis of Acute Kidney Injury in Newborns

Ioanna Argyri
1   National and Kapodistrian University of Athens, Medical School, Athens, Greece
,
Theodoros Xanthos
1   National and Kapodistrian University of Athens, Medical School, Athens, Greece
,
Marianna Varsami
1   National and Kapodistrian University of Athens, Medical School, Athens, Greece
,
Filippia Aroni
1   National and Kapodistrian University of Athens, Medical School, Athens, Greece
,
Apostolos Papalois
2   Experimental Research Centre, ELPEN Pharmaceuticals, Athens, Greece
,
Ismene Dontas
1   National and Kapodistrian University of Athens, Medical School, Athens, Greece
,
Vassillios Fanos
3   Puericulture Institute and Neonatal Section, Department of Clinical Medicine and Pediatric Sciences, Neonatal Intensive Care Unit, University of Cagliari, Cagliari, Italy
,
Nicoletta Iacovidou
4   2nd Department of Obstetrics and Gynecology, Neonatal Division, Aretaieio Hospital Medical School, National and Kapodistrian University of Athens, Greece
› Institutsangaben
Weitere Informationen

Publikationsverlauf

09. Januar 2012

31. Mai 2012

Publikationsdatum:
21. September 2012 (online)

Preview

Abstract

Acute kidney injury (AKI) refers to the rapid loss of renal function. In clinical practice, AKI is common among hospitalized patients of all age groups including neonates and remains an important cause of morbidity and mortality due to its late diagnosis and therefore delayed therapeutic intervention. Although the precise incidence of AKI in newborn is unknown, several studies have reported that 8 to 24% of all critically ill newborns in neonatal intensive care units may develop the condition. We aim at reviewing the existing literature on novel serum and urinary biomarkers and discuss their role in the early diagnosis and prognosis of AKI in newborns. Specifically, this review will focus on cystatin C (CysC), neutrophil gelatinase-associated lipocalin (NGAL) and interleukin-18 (IL-18) in serum and on CysC, NGAL, kidney injury molecule-1, and IL-18 in urine.